Development of new thiazolidine-2,4-dione hybrids as aldose reductase inhibitors endowed with antihyperglycaemic activity: design, synthesis, biological investigations, and in silico insights

• Príomhchruthaitheoirí: Abdelrahman Hamdi (Údar), Muhammad Yaseen (Údar), Wafaa A. Ewes (Údar), Mashooq Ahmad Bhat (Údar), Noha I. Ziedan (Údar), Hamed W. El-Shafey (Údar), Ahmed A. B. Mohamed (Údar), Mohamed R. Elnagar (Údar), Abdullah Haikal (Údar), Dina I. A. Othman (Údar), Abdullah A. Elgazar (Údar), Ahmed H. A. Abusabaa (Údar), Kamal S. Abdelrahman (Údar), Osama M. Soltan (Údar), Mostafa M. Elbadawi (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

This research study describes the development of new small molecules based on 2,4-thiazolidinedione (2,4-TZD) and their aldose reductase (AR) inhibitory activities. The synthesis of 17 new derivatives of 2,4-TZDs hybrids was feasible by incorporating two known bioactive scaffolds, benzothiazole hete...